These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17182861)

  • 21. [Possibilities and value in the drug therapy of tuberculosis].
    Sighart H
    Wien Med Wochenschr; 1977 Jun; 127(13):418-21. PubMed ID: 408982
    [No Abstract]   [Full Text] [Related]  

  • 22. [Experimental tuberculosis in mice, a model for the study of antitubercular chemotherapy].
    Rist N
    Arch Roum Pathol Exp Microbiol; 1971 Jun; 30(2):295-6. PubMed ID: 5004388
    [No Abstract]   [Full Text] [Related]  

  • 23. [Levofloxacin (Tavanic) in complex therapy of tuberculosis].
    Sokolova GB; Kunichan AD; Lazareva IaV
    Antibiot Khimioter; 2009; 54(1-2):31-7. PubMed ID: 19499715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The advantages of the antituberculosis regimens which include Sinerdol-EH, a new tuberculostatic of rifampicin-type.
    Păunescu E
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1983; 32(1):33-42. PubMed ID: 6312533
    [No Abstract]   [Full Text] [Related]  

  • 25. [Comparative genomics and anti-tuberculosis drug target discovery].
    Shi WJ; Zhang XL; Wang HH
    Zhonghua Jie He He Hu Xi Za Zhi; 2008 Jan; 31(1):54-7. PubMed ID: 18366909
    [No Abstract]   [Full Text] [Related]  

  • 26. [Evaluation of new antitubercular agents--new quinolones].
    Kawahara S; Eirei J
    Kekkaku; 1992 Oct; 67(10):679-82. PubMed ID: 1453572
    [No Abstract]   [Full Text] [Related]  

  • 27. Difficulties in the diagnosis and treatment of drug-resistant tuberculosis and tuberculous empyema.
    Glisson J; Mehta JB
    J Tenn Med Assoc; 1992 Sep; 85(9):419-22. PubMed ID: 1405623
    [No Abstract]   [Full Text] [Related]  

  • 28. Polymeric complexes of isonicotinic acid hydrazide with antituberculosis effects.
    Slivkin AI; Lapenko VL; Bychuk AI; Suslina SN; Slivkin DA; Kornienko SV; Belenova AS
    Bull Exp Biol Med; 2013 Oct; 155(6):764-6. PubMed ID: 24288761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Occurence of primary resistance in hospital patients with respiratory tuberculosis].
    Serdarević H; Bogdanović M; Travnik H; Simeonov L
    Tuberkuloza; 1966; 18(1-3):220-7. PubMed ID: 16296090
    [No Abstract]   [Full Text] [Related]  

  • 30. [Determination of Mycobacterium tuberculosis' sensitivity to pyrazinamide on a BACTEC-960 bacteriological analyzer].
    Irtuganova OA; Smirnova NS; Slogotskaia LV
    Probl Tuberk Bolezn Legk; 2003; (7):40-2. PubMed ID: 12939878
    [No Abstract]   [Full Text] [Related]  

  • 31. [Possibility of the intensification of tuberculosis chemotherapy and its limits].
    Naito M; Kanai K; Kondo E; Yamashita H; Matsui K
    Kekkaku; 1969 Nov; 44(11):377-93. PubMed ID: 4982567
    [No Abstract]   [Full Text] [Related]  

  • 32. An in vitro antituberculosis drug sensitivity of isolates of Mycobacterium tuberculosis from human cases of pulmonary tuberculosis.
    Shah VM; Jhala CI
    J Indian Med Assoc; 1976 Aug; 67(3):57-9. PubMed ID: 828192
    [No Abstract]   [Full Text] [Related]  

  • 33. Guidelines for chemotherapy of tuberculosis in Taiwan.
    ; ; ; ;
    J Microbiol Immunol Infect; 2004 Dec; 37(6):382-4. PubMed ID: 15599473
    [No Abstract]   [Full Text] [Related]  

  • 34. [Resistance of Mycobacterium tuberculosis to the major antitubercular drugs in pulmonary tuberculosis in children and youth previously untreated].
    Mordyński K; Piotrowski Z; Szymański A
    Gruzlica; 1968 Aug; 36(8):715-8. PubMed ID: 4972465
    [No Abstract]   [Full Text] [Related]  

  • 35. Models and approaches for anti-TB drug testing.
    Yasinskaya Y; Sacks L
    Expert Rev Anti Infect Ther; 2011 Jul; 9(7):823-31. PubMed ID: 21810054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Drug resistance of tubercle bacilli isolated from sputum in previously untreated pulmonary tuberculosis. 3].
    Nakai H; Maekawa N; Nakanishi M; Kawai M; Naito M
    Bull Chest Dis Res Inst Kyoto Univ; 1971 Jan; 4(1):15-24. PubMed ID: 5005481
    [No Abstract]   [Full Text] [Related]  

  • 37. [Reasons for drug-resistant tuberculosis emergence].
    Tu DH
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 Jun; 30(6):403-5. PubMed ID: 17673006
    [No Abstract]   [Full Text] [Related]  

  • 38. [Approaches to combined therapy of pulmonary tuberculosis in adolescents excreting drug-resistant Mycobacterium tuberculosis].
    Firsova VA; Rusakova LI; Grigor'eva ZP; Ryzhova AP; Iatskova TV; Poluéktova FG
    Probl Tuberk; 2001; (1):28-30. PubMed ID: 11337776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of saturation of Mycobacterium tuberculosis--a theoretical basis of the method of mazimum concentration of tuberculostatic preparations].
    Bondarev IM
    Probl Tuberk; 1974; 52(6):58-64. PubMed ID: 4211415
    [No Abstract]   [Full Text] [Related]  

  • 40. [Comparative data from an experimental-clinical study of new antituberculosis drugs].
    Utkin VV
    Antibiotiki; 1972 Sep; 17(9):851-6. PubMed ID: 4631726
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.